1. More intensive hepatitis C virus care models promote adherence among people who inject drugs with active drug use: The PREVAIL study.
- Author
-
Heo, Moonseong, Pericot‐Valverde, Irene, Niu, Jiajing, Norton, Brianna L., Akiyama, Matthew J., Nahvi, Shadi, Arnsten, Julia H., and Litwin, Alain H.
- Subjects
- *
ANTIVIRAL agents , *RIBAVIRIN , *HEPATITIS C virus , *DRUG utilization , *HEPATITIS C , *DIRECTLY observed therapy - Abstract
Keywords: adherence; DAA; drug use; HCV; PWID EN adherence DAA drug use HCV PWID 172 175 4 01/19/23 20230201 NES 230201 Abbreviations DAA direct-acting antiviral DTF daily time frame GT groups therapy HCV hepatitis C infection mDOT modified directly observed therapy OTP opioid treatment program PWID people who inject drugs SIT standard individual therapy SVR sustained virologic response INTRODUCTION Direct-acting antiviral (DAA) therapies are more effective for treating hepatitis C virus (HCV) with higher rates of sustained virologic response (SVR) and fewer side effects than older interferon-based treatments.[1] DAAs are effective even among people who inject drugs (PWID),[2] a population disproportionately infected by HCV.[3] Nonetheless, adequate adherence is crucial for PWID living with HCV to achieve SVR and reduce transmission, a public health goal which has been prioritized for global efforts to eliminate HCV by 2030.[4] How ongoing drug use interferes with HCV treatment adherence support remains unknown.[[5]] The PREVAIL study[2] was conducted in opioid treatment program (OTP) settings to test the effectiveness of three models of HCV care for PWID. Hepatitis C virus direct-acting antiviral treatment adherence patterns and sustained viral response among people who inject drugs treated in opioid agonist therapy programs. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF